Annovis Bio Partners With NeuroRPM To Integrate FDA-Cleared AI Movement-Tracking Platform Into Ongoing Parkinson’s Study

Annovis Bio, a Phase 3 clinical-stage biotech company developing the investigational oral therapy buntanetap for neurodegenerative conditions including Alzheimer’s disease and Parkinson’s disease, announced a new partnership with NeuroRPM to incorporate an FDA-cleared artificial intelligence platform into its ongoing Parkinson’s disease study.

The collaboration supports Annovis’ open-label trial in Parkinson’s patients (ANVS-25002), which is actively enrolling participants at 25 clinical sites across the United States. The study will evaluate buntanetap over a 36-month treatment period. 

As part of efforts to improve symptom tracking and enhance the overall data-collection process, the company will implement NeuroRPM’s AI-enabled medical device, the first FDA-cleared system designed to continuously monitor key Parkinson’s symptoms such as bradykinesia, tremor, and dyskinesia. These metrics will function as digital biomarkers, offering real-time insights into how symptoms evolve over the course of the study.

Cheng Fang, Ph.D., Senior Vice President of Research and Development at Annovis Bio, said the partnership represents an important step toward generating richer, data-driven insights in Parkinson’s research. Cheng Fang noted that the AI-derived movement data will complement existing study measurements and strengthen the monitoring of disease progression. 

According to Dr. Fang, the combined dataset of traditional clinical assessments alongside digital biomarkers is expected to yield a deeper understanding of disease trajectory and help inform the design of future clinical trials.

The integration of NeuroRPM’s platform marks a strategic advancement in Annovis Bio’s approach to long-term Parkinson’s disease research, supporting the company’s commitment to evidence-based development of buntanetap and next-generation digital monitoring tools.